These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 15368657)
1. Cardiovascular combinations. Glass G Nat Rev Drug Discov; 2004 Sep; 3(9):731-2. PubMed ID: 15368657 [No Abstract] [Full Text] [Related]
2. What future does the pharmaceutical industry have in the cardiovascular world? Braunwald E Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415 [No Abstract] [Full Text] [Related]
4. [New cardiovascular-active drugs]. Bölter C Z Arztl Fortbild (Jena); 1984; 78(19):797-800. PubMed ID: 6506791 [No Abstract] [Full Text] [Related]
5. [Problems in scientific drug therapy from a socio-hygienic point of view]. Kobler A; Lehmann G Z Arztl Fortbild (Jena); 1981 Oct; 75(19):906-8. PubMed ID: 7314685 [No Abstract] [Full Text] [Related]
6. PHARMAC and cardiovascular health in New Zealand. Moodie P N Z Med J; 2008 Mar; 121(1270):102-5. PubMed ID: 18364762 [No Abstract] [Full Text] [Related]
8. Promises kept and broken: new pharmaceuticals. Malik P Can J Cardiol; 2002 May; 18(5):493-4. PubMed ID: 12032574 [No Abstract] [Full Text] [Related]
10. [The biophysiology of the cardiovascular system and its therapeutic implications]. Michel D Internist (Berl); 1984 Aug; 25(8):478-84. PubMed ID: 6384113 [No Abstract] [Full Text] [Related]
11. Corporate influence over planning and presentation of clinical trials: beauty and the beast. Fuchs FD Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):7-9. PubMed ID: 20014930 [No Abstract] [Full Text] [Related]
13. Cardiovascular drugs and the elderly population. Lapinski ML Heart Lung; 1982; 11(5):430-4. PubMed ID: 6921190 [No Abstract] [Full Text] [Related]
14. The polypill and medicines access: two decades and counting. Rodgers A; Smith R BMJ; 2023 Aug; 382():1847. PubMed ID: 37562792 [No Abstract] [Full Text] [Related]
15. Scientific development of the CNIC cardiovascular polypill: from conceptualization to clinical efficacy. Castellano JM; Fuster V Rev Esp Cardiol (Engl Ed); 2023 Dec; 76(12):1055-1060. PubMed ID: 37866619 [No Abstract] [Full Text] [Related]
17. The polypill: from concept and evidence to implementation. Yusuf S; Pinto FJ Lancet; 2022 Nov; 400(10364):1661-1663. PubMed ID: 36243022 [No Abstract] [Full Text] [Related]
18. The utility of cardiovascular drugs in the treatment of cerebrovascular disease. Bösel J; Amiri H Curr Opin Investig Drugs; 2010 Sep; 11(9):1015-24. PubMed ID: 20730696 [TBL] [Abstract][Full Text] [Related]
19. [Methods of evaluating drug therapy, particularly in cardiovascular diseases]. Lövy O; Toman J Cesk Zdrav; 1984 Sep; 32(8-9):361-5. PubMed ID: 6509673 [No Abstract] [Full Text] [Related]
20. Polypill holds promise for people with chronic disease. Wise J Bull World Health Organ; 2005 Dec; 83(12):885-7. PubMed ID: 16462975 [No Abstract] [Full Text] [Related] [Next] [New Search]